31
Participants
Start Date
November 30, 2012
Primary Completion Date
July 31, 2015
Study Completion Date
July 31, 2015
BEZ235 (Stage 1)
The investigational study drug used in this trial was BEZ235, which was supplied as 50mg, 200mg, 300mg, and 400mg solid dispersion sachets. Supply as 200mg and 50mg were provided for dose reduction. Patients were instructed to take the contents of one sachet of BEZ235 twice a day in the morning within 30 minutes after a light meal (breakfast).
Novartis Investigative Site, Leuven
Montefiore Medical Center SC-2, The Bronx
Novartis Investigative Site, Milan
Novartis Investigative Site, Milan
Novartis Investigative Site, Madrid
Ohio State Comprehensive Cancer Center/James Cancer Hospital SC, Columbus
Novartis Investigative Site, Essen
Indiana University SC, Indianapolis
Novartis Investigative Site, Florence
Novartis Investigative Site, Lyon
Novartis Investigative Site, Villejuif
Dana Farber Cancer Institute GastrointestionalCancer Clinic, Boston
Novartis Investigative Site, Vienna
Novartis Investigative Site, Rotterdam
Novartis Investigative Site, Barcelona
Novartis Investigative Site, L'Hospitalet de Llobregat
Novartis Investigative Site, Manchester
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY